Company Overview and News
With trade war fears plaguing the market, Chinese stocks have been receiving some bad rap recently. But don’t let this distract you. The top China-based stocks present stellar investing opportunities. And you don’t just have to take my word for it. Here we use TipRanks to pinpoint the best Chinese stocks according to the Street. This website tracks the latest ratings from over 4,800 analysts — so we can find the most highly-rated stocks with just a couple of clicks.
WFC WFCNP WFC.WS F WFC.PRL WFC.PRJ WFC.PRT WB BABA WFC.PRR WFC.PRQ SINA WFC.PRP WFC.PRO WFC.PRN 0700 BGNE WFC.PRY WFC.PRX BIDU WFC.PRW WFC.PRV
CUSIP No: G81477104
CUSIP No: G81477104
Nasdaq-listed Momo, whose net income rose 60 per cent to a record US$129.9 million in the March quarter, now has a higher market capitalisation than Sina Corp
From July, Nasdaq will provide its Asia-Pacific customers direct access to its market data via three data centres in Hong Kong
The world’s No. 4 smartphone maker will go on the road by end-June to persuade US and European institutional investors to value Xiaomi at no less than US$70 billion
Volatility in the core business is expected as the underlying product and interest in it is volatile.
SINA Corporation’s (SINA - Free Report) first-quarter 2018 non-GAAP earnings of 47 cents per share beat the Zacks Consensus Estimate by a couple of cents but declined 3 cents from the year-ago quarter. Net revenues grew 59% to $441 million and beat the Zacks Consensus Estimate of $440 million. Non-GAAP net revenues also grew 59% to $438.1 million. Quarter Details Advertising revenues surged 61% year over year to $367.
LRCX SINA MU WDC
Table of Contents
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to SINA / Sina Corp. on message board site Silicon Investor.
as of ET